News and Trends 16 Oct 2017 Interview: On the Future of iPS Cells and why Partnering is so Important in this Field In our first part of the interview with Dr David Hallett, Executive Vice President at Evotec, we discussed the uniqueness of Induced Pluripotent Stem Cells (iPS Cells), novel developments occurring in iPS Cell research, and the challenges researchers face. Let us have a short recap of what we have learned so far: iPS Cells were […] October 16, 2017 - 9 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2017 New Stem Cells Could Take Cell Research and Therapies to the Next Level British researchers have created a new type of stem cell in mice. It has even greater potential than current cell lines in research and in the clinic. Stem cells have huge potential in research and therapeutics and overcome the limitations of current cell lines – embryonic and induced pluripotent stem cells. Findings published in Nature report that researchers at […] October 16, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 16 Oct 2017 Meet the Former Banker at the Helm of Denmark’s Healthcare Giant, Novo Holdings Kasim Kutay has ridden the biotech investment wave. First, he helped build Morgan Stanley’s European healthcare group, then did the same at Moelis & Co and now he heads Novo Holdings, the majority shareholder of Danish household biotech names NovoZymes and Novo Nordisk. I asked him about the company’s healthcare investment strategy and his CEO […] October 16, 2017 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 14 Oct 2017 Art and Biology Meet at Nonhuman Networks Exhibition in Berlin The exhibition Nonhuman Networks at Art Laboratory Berlin invites us to connect with other organisms and rethink our relationship with the environment. For those of us living in the Western world, our whole culture seems to revolve almost exclusively around ourselves. Despite having evolved within an ecosystem with a huge and fascinating diversity, we tend […] October 14, 2017 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 13 Oct 2017 German Biotech Gets €47M To Treat Painful Inflammatory Disease InflaRx has raised $55M (€47M) in a Series D fundraising in order to get its lead anti-inflammatory drug, IFX-1, through late-stage development. A year after its €31M Series C, InflaRx is closing a Series D round. The company has raised a total of $55M (€47M) from a team of US investors co-led by Bain Capital Life Sciences, […] October 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Oct 2017 Why Might Biotechs Lose Easy Access to Scientific Papers? Five publishers have ordered ResearchGate to take down articles. Researchers might continue to get around the paywall with Sci-Hub and other initiatives. ResearchGate, described as ‘Facebook for scientists’, has over 13 million members. It has raised more than $80M (€68M) from investors including Bill Gates and the Wellcome Trust. But, five scientific publishers including Elsevier and Wiley have clubbed […] October 13, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 13 Oct 2017 Sanofi Invests €170M in French Facilities to Expand Flu Vaccine Supply Sanofi Pasteur will expand its main vaccine manufacturing site to increase distribution of its quadrivalent flu vaccine VaxigripTetra around the world. Sanofi will invest €170M in expanding its vaccine production facilities in Val de Reuil, France, which also hosts its global vaccine distribution center, from which it currently ships 900 million vaccine doses a year. The company plans to complete the expansion by […] October 13, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Startup Scout 13 Oct 2017 This French Biotech is Taking On CNS Diseases of the Young and the Elderly This week we’re in Castres in the South of France to visit Neurolixis. This biotech is taking on diseases of the CNS, such as Parkinson’s, depression and schizophrenia. Mission: Neurolixis is tackling CNS and mood diseases, a number of which lack effective treatment options at the moment. The biotech currently has two candidate drugs undergoing […] October 13, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2017 Can Catalonia Keep its Record Biomedical Investment After the Bank Drain? A new study reveals Catalonia achieved a record investment in biomedicine last year. But can the region keep it up after its main banks moved out last week? CataloniaBio has released an annual report on the performance of the biomedical sector in Catalonia. The results reveal that the sector raised a record €153M in 2016, an […] October 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2017 This New Approach Simplifies Protein Analysis Analyzing your protein sample can be a right hassle. It takes time, energy and a LOT of nerves. Especially, when the experiment has not worked out the way one wanted it to. But there is a way around it, and this company has found the solution! The use of protein biomarkers has become an essential […] October 12, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2017 No More Seasonal Flu Shots: British Biotech’s Universal Antiviral Raises £13M VirionHealth kicks off the development of a broad spectrum antiviral for all influenza strains and other viruses like RSV with a £13M investment in Series A. VirionHealth is developing a new type of antiviral therapy with the potential to target multiple types of viruses at once. The treatment is based on natural antivirals called defective interfering viruses. They consist […] October 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2017 Deadly Parasite Could be Stopped by Scottish Researchers’ Discovery A study in Scotland has improved our understanding of how a dangerous parasite functions, creating a new target for combatting deadly infections. Research from the University of Edinburgh has identified a therapeutic target in Leishmania, a parasite that infects 1 million people each year, resulting in 20,000-30,000 deaths. The study, published in the Journal of Molecular Biology, used clever […] October 12, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email